IDDI

PASSION. SCIENCE. EXPERIENCE.



Mastering IDMCs:

Essential Insights for Pharmaceutical and Biotech Companies

From 280+ Successfully Executed IDMCs Over 3 Decades

IDDI.com

THE ROLE OF INDEPENDENT DATA MONITORING COMMITTEES (IDMCS) IS CRITICAL FOR ENSURING THE INTEGRITY AND SAFETY OF THE STUDY AND PATIENTS.

At IDDI (International Drug Development Institute), we are experts in IDMCs, regulatory statistics.

Our e-book is designed to provide the knowledge and tools needed to effectively plan and execute IDMCs in clinical trials.

This comprehensive guide covers:

- Introduction to IDMCs and Their Importance
- Key Players and Roles in the IDMC Process
- IDMC Processes, Contracts and Regulatory Compliance
- The Role of the Statistical Data Analysis Center (SDAC)
- Crafting Effective IDMC Reports

Whether you are a professional from a pharmaceutical or from a biotech company, this e-book was created to offer valuable insights that will enhance your understanding and execution of IDMCs.

Acknowledgement

Facundo Zaffaroni, Senior Biostatistician, IDDI
Emmanuel Quinaux, Director, Biostatistical Services, IDDI
Tara Kervin, VP, Global Operations & Consulting; VP, IDDI Inc
Geneviève Sturbois, Associate Director, Biostatistics, IDDI
Sarah Hale, Associate Director, Biostatistical Services, IDDI
Thao Pham, Team Leader, Project Coordinators, IDDI
Celeste Campbell, Senior Project Coordinator, IDDI

Table of **contents**

1

When & Why IDMCs **Matter**

Introduction

As revealed in the must-read book Fundamentals of Clinical Trials (Fifth Edition) by Lawrence M. Friedman and colleagues [1]:

> **During the trial, response variables need to be monitored for early dramatic benefits or potential harmful effects or futility. Monitoring should be done by a person or group independent of the investigator**

Over eight decades following the inception of New Drug Applications (NDAs) under the Food, Drug, and Cosmetic Act of 1938, clinical research is entering a revamped and redefined era of clinical trials wherein patient-centricity is a focal point of the drug development process – shifting the paradigm away from an investigator-subject model to that of participant and collaborator.

Now more than ever, we see the importance of an independent entity entrusted to uphold the ethical necessity to maintain equipoise in a randomized clinical trial and protect the interests of the patients.

An Independent Data Monitoring Committee (IDMC), also referred to as a Data Monitoring Committee (DMC) or a Data and Safety Monitoring Board (DSMB), is a multi-disciplinary group of independent experts. They evaluate the cumulative clinical trial data on an ongoing basis.

Based on their evaluations, they recommend to the trial sponsor whether to continue, modify, or stop a trial due to trial performance issues, safety concerns, overwhelming benefit, or treatment futility.

If the study is unlikely to produce an interpretable result or produce a result within a reasonable period, the IDMC may feel ethically compelled to recommend action

They are integral to the success and ethical conduct of clinical trials.

Their primary role is to monitor the safety and efficacy of the new treatment and maintain the trial's credibility and integrity by providing independent oversight.

As these committees are truly independent, meaning they have no financial or scientific interest in the trial's continuation or results, they are in a great position to mediate between the different interests of trial sponsors and patients.

They can focus on the safety of the experimental treatment, meet the regulatory requirements for reporting side effects, consider the sponsor's financial interest in ending the trial early if the treatment is ineffective or very successful, and support the investigator's goal to quickly share new scientific findings and best treatment practices.

SAFETY | EFFICACY | CREDIBILITY | INTEGRITY | INDEPENDENCY

Contexts Requiring IDMCs

According to the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) E6 [2]:

> **The sponsor may consider establishing an independent data-monitoring committee (IDMC) to assess the progress of a clinical trial, including the safety data and the critical efficacy endpoints at intervals, and to recommend to the sponsor whether to continue, modify, or stop a trial.**

As per ICH E9 [3]:

> **An IDMC may be established by the sponsor to assess at intervals the progress of a clinical trial, safety data, and critical efficacy variables and recommend to the sponsor whether to continue, modify or terminate a trial.**

The Food and Drug Administration (FDA) guidance "Establishment and Operation of Clinical Trial Data Monitoring Committees" from 2006 [4] states that sponsors of clinical trials should consider using an IDMC to further protect study patients when:

- The study endpoint is such that a highly favorable or unfavorable result, or even a finding of futility, at an interim analysis might ethically require termination of the study before its planned completion.
- There are a priori reasons for a particular safety concern, such as, if the procedure for administering the treatment is particularly invasive.
- There is prior information suggesting the possibility of serious toxicity with the study treatment.
- The study is being performed in a potentially fragile population such as children, pregnant women, the very elderly, or other vulnerable populations, such as those who are terminally ill or of diminished mental capacity.
- The study is being performed in a population at elevated risk of death or other serious outcomes, even when the study objective addresses a lesser endpoint.
- The study is large, of long duration, and multi-center.

Contexts Requiring IDMCs

That said, the 2024 FDA draft guidance, “Use of Data Monitoring Committees in Clinical Trials” [5] (hereon referred to as the ‘2024 FDA Draft Guidance’), also advises considering whether an IDMC review is practical for a trial and whether it could have a meaningful impact on a trial’s conduct.

For instance, having an IDMC might be impractical whenever a trial’s enrollment is expected to be completed quickly and the follow-up period is short.
In such cases, specific mechanisms should be developed to allow timely IDMC evaluation, such as having pauses in advance of dose escalation.
More details can be found in Section IV of the 2024 FDA Draft Guidance.

Although much of the literature and context of IDMCs is premised on the assumption of a randomized double or triple-blind trial design, IDMCs are utilized and can bring value to randomized open-label trials or even single-arm trials by helping minimize the potential of the introduction of bias from the study team and mitigating the appearance of a conflict of interest.

Purpose of IDMCs

The IDMC has a vital role in randomized clinical trials by fulfilling several key responsibilities:

- **Ensuring patient safety:** Monitoring adverse events and ensuring that any potential risks to patients are promptly identified and addressed.
- **Maintaining trial integrity:** Ensuring that the trial is conducted according to the established protocol and that the data collected is reliable and accurate.
- **Providing independent oversight:** Offering an unbiased review of the trial's progress, free from the influence of sponsors or investigators.

The most common and recognized purpose of an IDMC is to monitor clinical trials for safety. Yet, it is fundamental to note that trial monitoring of interim data for safety purposes does not imply that only safety data should be reviewed by the IDMC; potential benefits must also be considered.

The safety and interests of the patients and the sponsor are best protected when monitored in the context of risk-benefit assessment. Therefore, trial sponsors and the independent statistical groups reporting to IDMCs should develop a plan to provide the IDMC with sufficient data and analyses for comprehensive benefit-risk determinations.

So, in addition to safety, IDMCs monitor:

- **Efficacy:** Evaluating whether the treatment is demonstrating the desired benefit.
- **Futility**: Assessing whether the trial is unlikely to achieve its intended outcomes.
- **Adaptations to trial design**: Recommending adjustments to improve trial outcomes based on interim data (More details can be found in Section VI.C.2.d of the 2024 FDA Draft Guidance).

This holistic approach allows the IDMC to guide the trial with a focus on both safety and efficacy, ensuring balanced decision-making for patient protection and scientific integrity.

IDMC Members Profile

IDMC MEMBERS SHOULD:

- **Have relevant expertise and experience** in the disease/condition under investigation and in clinical trials.
- **Be independent (external) of the sponsor,** without significant conflicts of interest.
- **Have flexibility in their schedules** to handle urgent situations requiring quick responses or to be available for ad hoc meetings on short notice.
- **Come from diverse countries or geographic regions** per the makeup of the trial operations and population.
- **Have a good understanding of clinical trial design** and the importance of randomization, as well as regulatory requirements.
- **Possess effective communication and decision-making skills,** analytical thinking, and a collaborative spirit.

The IDMC statistician should also **be familiar with statistical methods for safety and efficacy analyses,** as well as with **statistical methods for interim analysis (such as group sequential and adaptive designs)**, including the calculation and interpretation of conditional power. The IDMC statistician member should **be able to explain these methods to the other members.**

Most IDMC members should have **prior experience serving on IDMCs**.
To prepare a new generation of qualified IDMC members, a combination of training and experience might be useful.

It is worth considering the inclusion of a non-voting 'new member' without prior IDMC experience but with substantive expertise in areas of research or practice relevant to the IDMC's deliberations. This 'new member' could benefit from the mentorship of experienced members.

Sponsors have found success in widening their pool of competent IDMC members by supporting such experience-generating and mentorship opportunities. This can easily be achieved by inviting an IDMC to nominate an individual(s) to serve as a non-voting member(s) of the IDMC to shadow the process over the course of the trial.

IDMC Members Profile

DIFFERENT TYPES OF IDMC MEMBERS:

- **CLINICAL EXPERTS:**

Often physicians or specialists in the disease or therapeutic area being studied in the trial. Their role is to assess the safety and efficacy of the treatment based on clinical endpoints and to evaluate any concerning safety trends.

- **BIOSTATISTICIANS:**

They play a critical role in the analysis and interpretation of data. They review unblinded data to ensure the trial's statistical validity.

- **ETHICISTS**:

They ensure that the trial adheres to ethical guidelines, particularly concerning participant safety and informed consent. They may weigh in on the ethical implications of continuing or stopping the trial, especially in cases where there are concerns about participant harm or benefit.

- **PATIENT ADVOCATES**:

In some cases, a patient advocate or representative may be included to provide insights from the patient's perspective. This member ensures that patient concerns and the impact of the intervention on quality of life are considered in IDMC discussions.

Key Insights and Strategies

IMPORTANCE OF TIMELY AND COMPREHENSIVE REPORTING

One of the critical elements for an effective IDMC is receiving timely and comprehensive interim reports. According to DeMets and Wittes (2022) [6], the current state of IDMC reports often falls short, with reports being lengthy, unfocused, and nearly unreadable. Improving the quality of these reports is essential for IDMCs to fulfill their ethical, clinical, and scientific responsibilities effectively.

STRUCTURED AND FOCUSED REPORTING

The ideal IDMC report should be clear, complete, and comprehensible, focusing on what the IDMC needs to know.

Key elements should include, if applicable:

- **Patient recruitment:** Data on the number of patients enrolled and their demographics.
- **Data availability and currentness:** Information on how up-to-date the data is.
- **Baseline characteristics:** Comparability of intervention arms at baseline.
- **Disposition of patients:** Details on patient retention, dropouts, and adherence to the protocol (including exposure to the intervention).
- **Adverse events:** Summary and analysis of significant adverse events and other relevant safety information.
- **Efficacy metrics:** Interim efficacy data to evaluate the potential benefits of the intervention.

TRAINING AND RESOURCES

Effective IDMC meetings require well-trained members who understand their roles and responsibilities. Training modules provided by organizations like the Society for Clinical Trials (https://www.sctweb.org/dmctraining/) [7] can improve the understanding of IDMC functions and the content of IDMC reports.

Having an expert Statistical Data Analysis Center (SDAC) can ensure that the IDMC receives high-quality, unbiased data analysis that lends to speedy and well-informed recommendations. For trial sponsors, it is fundamental that the selection of the SDAC is based on expertise rather than just the price. Details on a series of questions to ask the SDAC can be found in DeMets and Wittes (2022) [6].

CONCLUSION

> IDMCs play a critical role in ensuring the safety and integrity of clinical trials. By understanding when and why IDMCs are needed and focusing on high-quality reporting and training, trial sponsors and investigators can reduce the risk of continuing an unethical or harmful study.

2

Key Players & **Roles** in the IDMC Process

Key Players and Roles

INTRODUCTION

This chapter presents the key players involved in the IDMC process, focusing on their roles and responsibilities within randomized double-blind and open-label trials. It highlights the importance of maintaining strict boundaries between blinded and unblinded parties to preserve the integrity of the trial and ensure unbiased decision-making.

KEY PLAYERS AND ROLES

The details described below apply to randomized double-blind trials, where the sponsor/Study teams should remain blinded until the final database unblinding and should not know which treatment each patient is receiving.

These details also apply to randomized open-label trials where the sponsor study team should not have access to summarized by-arm results during the trial.
Providing unblinded information during the trial could inadvertently influence the sponsor in making decisions related to trial modifications.

If the sponsor later expresses the need to make changes to the study inclusion criteria, the endpoints, sample size, or other relevant factors, the risk of regulatory authorities casting doubt upon the validity of the study and not approving a protocol amendment greatly increases.

Decisions on protocol modifications are best made by those without knowledge of the interim data. Therefore, minimizing exposure to such data helps ensure that trial adjustments, whether due to scientific advancements or logistical challenges, are made objectively. Implementing proper safeguards around access to interim data supports a more robust and unbiased trial outcome.

Key Players and Roles - IDMC Members

CLOSE COLLABORATION, COMMUNICATION, AND TRUST BETWEEN THE SPONSOR, THE IDMC, AND THE SDAC ARE ESSENTIAL TO ENSURE AN EFFICIENT IDMC REVIEW.

IDMC MEMBERS:

Typically, they are composed of a *small number of clinicians* (some with expertise in the indication under investigation, some with expertise in expected adverse events), *one statistician*, and, in some cases, *patient advocates or ethicists.*

They are responsible for **independently reviewing data** and **providing unbiased recommendations** to ensure both the scientific integrity and ethical conduct of the trial.

STATISTICAL DATA ANALYSIS CENTER (SDAC):

An independent company or team that supports IDMCs. The SDAC study team will be comprised of *biostatistician(s)* and *a project coordinator* who play a critical role in maintaining the independence and accuracy of the data reviewed by the IDMC. They are responsible for:

- **Preparing and distributing** unblinded reports for the IDMC, ensuring data integrity and facilitating objective decision-making.
- **Maintaining flexibility** to respond to ad hoc IDMC requests.
- **Offering logistical assistance**, such as meeting scheduling, drafting meeting minutes, and supporting the delivery and archival of the IDMC recommendations, if requested.
- If requested, assisting sponsors with **identifying IDMC members**, **facilitating** the preparation of their contracts, and ensuring timely payment of honoraria while adhering to legal transparency and reporting requirements.
- **Attending meetings**, **presenting the report/analyses** to the IDMC, **answering questions** related to the report. Of note, we recommend that two to three members from the SDAC attend IDMC meetings. A reporting biostatistician to lead the closed session in collaboration with the IDMC Chair, while an additional biostatistician or statistical programmer assists with data retrieval and on demand analyses. Additionally, a project coordinator should be present to provide administrative and operational support, including note-taking and meeting coordination.

Key Players and Roles - Sponsors

SPONSOR:

Pharmaceutical or biotech companies funding the trial. They are responsible for:

- **Appointing** an IDMC before the start of the trial and ensure its independence.
- **Advising** the IDMC and SDAC on any scientific, clinical, or statistical issues regarding the study (intervention) and promptly providing any relevant updates.
- **Responding** to IDMC recommendations and follow up on any commitments.
- **Providing the SDAC with all necessary data** for preparing reports. The SDAC should have access to all available data, including the unblinded randomization and efficacy data, to enable risk:benefit assessments and to respond to ad hoc IDMC requests. Routine data transfers should be planned (not only before regular IDMC meetings) to allow the SDAC to respond to ad hoc IDMC requests without alerting the sponsor.

Figure 1 below illustrates the flow of communication and interaction between these three key players, highlighting their roles and the exchange of critical information during the IDMC process.



CONCLUSION

> IDMCs are essential for the successful conduct of randomized trials, ensuring patient safety and maintaining data integrity. By understanding their functionality and the roles of involved parties, stakeholders can optimize the effectiveness of IDMCs in RCTs.

3

The IDMC Process – From **Experts' Contracting** to **Regulatory Compliance**

The IDMC Process

INTRODUCTION

This chapter provides a comprehensive look at the essential components of the IDMC process, including elements such as:

- IDMC Contracting;
- IDMC Charter;
- The various meeting structures and their minutes.

By understanding these components, stakeholders can significantly **improve clinical trial oversight** and **ensure both the safety of patients** and **the integrity of trial data.**

IDMC Contracting

Several things should be considered when developing IDMC member agreements.

- First, the **crucial responsibilities** that the IDMC undertakes for the safety of trial participants may heighten the risk of legal liability for IDMC members.
    - IDMC members *should be adequately protected* under specific circumstances related to the trial(s) they oversee, as an inappropriate IDMC agreement could place members in a situation where their personal interests (i.e., concerns with legal liability) conflict with their duty to protect the interests of trial subjects.
    - The members' contracts should include language concerning *liability and indemnification to ensure a fair distribution of legal responsibility between the sponsor and the IDMC members*, including IDMC member protection against third-party claims due to the harmful effects of an investigational product.
- Second, the **agreements define the honoraria payments** that will be made to the IDMC members. The agreed-upon rates should be fair, but not extravagant.
    - The IDMC members' contracts should be reviewed and signed prior to the first IDMC meeting (the 'Kickoff' or 'Organizational' meeting). Following each IDMC meeting, an invoicing form should be sent to the IDMC members, who will verify the included details and return the invoice for payment. Honoraria payments should be processed promptly, ideally within 30 days of receiving the completed invoice.

IDMC Charter Summary

The IDMC Charter is a critical document describing how the IDMC will operate and how the sponsor, SDAC, and IDMC will interact. It should provide proper guidance to the IDMC without being overly detailed or restrictive.

The Charter should **specify the primary responsibilities of the IDMC** in relation to the sponsor.

It should address:

- potential conflicts of interests IDMC members may have,
- procedures for maintaining confidentiality,
- the format for IDMC meeting sessions, reports and minutes,
- additional details regarding communication pathways,
- and the statistical guidelines for interim analyses.

Section VI.B of the 2024 FDA Draft Guideline provides a list of the minimum elements they recommend a Charter should include.

The IDMC Charter **should not include protocol details** that may change through protocol amendment, names of individual sponsor team members, or restrictions on the recommendations the IDMC may make.

It **may include appendices** such as

- a template IDMC recommendation form,
- a list of sponsor team members along with their roles and contact information,
- a proposed table of contents for reports.

These appendices may be updated without requiring a full re-signing of the IDMC Charter to ease administrative burden.

The Charter can be first prepared by the sponsor and presented to the IDMC and SDAC for discussion and agreement. Alternatively, it can be prepared by the SDAC or IDMC itself, following a presentation to the sponsor.

Regardless of which key player (IDMC, sponsor, SDAC) initially drafts the Charter, all three key players should be involved in the creation and approval of the document.

The Charter should be in place before any planned data analysis and, ideally, before the initiation of the trial and patient enrollment.

IDMC Meetings

FIRST IDMC MEETING: ORGANIZATIONAL (KICKOFF) MEETING

Three key players will attend: the sponsor's study team representatives, the SDAC, and the IDMC.

This kickoff meeting should take place **before the first patient is enrolled in the study.** It allows for an open discussion among the different parties without concerns about unblinding or compromising data integrity, and provides the IDMC an opportunity to recommend study conduct strategies before the study begins.

For this kickoff meeting, an in-person meeting/gathering is generally preferred to **facilitate building a strong foundation of collaboration and effective communication** to carry forward throughout the study.
This meeting serves to **introduce the attendees and clarify their roles** and **responsibilities**.

- The sponsor will present:
  - the study drug,
  - the protocol,
  - previous clinical study results,
  - and a review of the known safety profile of the study drug.

.

- The Charter and the planned content of the IDMC report may be reviewed during this meeting before final approval.

- The IDMC will also agree on the timing of data review meetings and the transfer/access of IDMC reports.

IDMC Meetings

REGULAR IDMC DATA REVIEW MEETINGS

Regular review meetings are pre-scheduled at consistent intervals. These meetings will typically **include an open session** and **a closed session.**

- During the **open session,** attended by the IDMC members, sponsor, and members of SDAC, the sponsor **will update the IDMC members on trial operations**. Any discussions during this session must remain blinded.
- During the **closed session**, attended only by the IDMC members and the SDAC, the IDMC will **review the unblinded study report** produced by the SDAC and agree on **recommendations** to communicate to the sponsor.
- These recommendations may include whether **to continue, modify, or stop the trial** due to performance issues, safety concerns, overwhelming benefit, or treatment futility.

As discussed in Chapter 1, the IDMC may also recommend actions if the study is unlikely to produce an interpretable result or if the result is not expected within a reasonable period. The IDMC should develop the recommendations by consensus rather than through voting.

After the closed session is over, an executive session may take place. This session is restricted to the voting members of the IDMC, allowing them to speak confidentially if they are dissatisfied with the presentation made by the SDAC.

AD HOC MEETINGS

Ad hoc meetings can be scheduled to address emerging safety issues, or other critical matters at the IDMC's discretion, and may be held without the sponsor's knowledge. The IDMC may also recommend modifications to the regular data review meeting schedule at any time.

Minutes

Documentation of IDMC meetings and any recommendations may need to be provided to IRBs and regulatory authorities, so strong record-keeping is essential.

- Meeting minutes must document the factors considered by the IDMC when formulating their recommendations, as well as the sponsor's responses to previous IDMC recommendations.
- Minutes can also be a useful tool in the ongoing data review process, serving as a reminder to the IDMC of previous discussions and data trends. However, the documentation of IDMC discussions also requires balancing transparency with confidentiality.
- The recording of IDMC meetings is discouraged, and minutes should not attribute comments to specific members unless otherwise requested (e.g., an IDMC member would like his or her dissent with the opinion of the other Committee members to be documented).

Typically, two versions of the meeting minutes will be issued:

OPEN SESSION MINUTES:

Summary of the open session presentation from the sponsor, which often *details the trial and enrollment status, relevant study document updates* (e.g., protocol amendments), and an *overview of blinded disposition and safety data*.

These minutes also document the *blinded questions* or comments from the IDMC to the sponsor.

CLOSED SESSION MINUTES:

Summary of the unblinded data reviewed during the closed session, *emphasizing discussions that led to recommendations made by the IDMC*.

These minutes are maintained by the SDAC and must *remain confidential* until the trial concludes and unblinding has occurred.

Meeting minutes will be approved by IDMC members, or at least by the IDMC Chair, following the process specified in the IDMC Charter.

Regulatory Guidelines for Compliance

Ensuring that IDMC activities comply with relevant regulatory frameworks is essential for the approval and success of clinical trials. Below are summaries of key regulatory when working with IDMCs. For detailed information, please refer to the respective official guidelines provided by regulatory authorities:

- **FDA Guidelines**: Focus on safety reporting, risk assessments, and interim data monitoring during clinical trials, emphasizing patient safety and trial integrity. Detailed guidance can be found in FDA's official documentation, but as already mentioned here in the e-book, the Guideline from 2006 and the Draft Guideline from 2024 are two of the relevant ones on the topic.

- **ICH Guidelines**: International guidelines on Good Clinical Practice (GCP), emphasizing the importance of data integrity and patient safety, along with ICH E9, which provides statistical principles for designing, conducting, analyzing, and assessing clinical trials of an investigational product within its comprehensive clinical development plan.

- **EMA Guidelines**: The European Medicines Agency provides guidelines for data monitoring and safety oversight, emphasizing best practices for IDMC operations within the European regulatory framework5.

- **Compliance Strategies**:
  - **Regular Audits**: Conducting periodic audits to ensure adherence to regulatory standards.
  - **Documentation**: Maintaining thorough and accurate records of all IDMC activities and decisions.

CONCLUSION

> By understanding and implementing best practices for the IDMC Charter, data access, IDMC related meetings, and regulatory compliance, stakeholders can optimize their clinical trial oversight and outcomes.

The Power of a **Good SDAC**

Qualities of a Good SDAC

A STRONG STATISTICAL DATA ANALYSIS CENTER (SDAC) IS CRUCIAL FOR A SUCCESSFUL IDMC AND WELL EXECUTED TRIAL.
AN EFFECTIVE SDAC ENSURES THE INTEGRITY AND RELIABILITY OF DATA, WHICH IS ESSENTIAL FOR INFORMED DECISION-MAKING BY IDMCS.

This section explores the qualities of a good SDAC, the risks associated with sponsor-led programming, and the advantages of independent programming by an SDAC.

EXPERTISE:

SKILLED BIOSTATISTICIANS EXPERIENCED IN CLINICAL RESEARCH:

The SDAC should be staffed with biostatisticians who have expertise in analyzing clinical trial data and interpreting results. The ability to read and understand not only a clinical trial protocol, but also related documents essential to the operation of a trial and the experience of the patients (e.g., Informed Consent Form, Investigator's Brochure) – and how these materials can be best utilized to support the IDMC. Experience in adaptive designs, including interim analysis, is necessary given the increasing use of these designs.

KNOWLEDGE OF REGULATORY STANDARDS:

The SDAC should be well-versed in the regulatory requirements for clinical trials, including the guidelines set by regulatory bodies such as the FDA or EMA (European Medicines Agency). A strong SDAC is able to gently manage an IDMC that is less well-versed on the regulatory ramifications of certain IDMC recommendations and actions.

SKILLED IN STATISTICAL ANALYSIS

Their expertise ensures that data is analyzed accurately and effectively, providing reliable insights for IDMCs. Such members of the SDAC must be able to make thoughtful recommendations for appropriate ad hoc analyses to best answer IDMC questions, as well as other programming derivations and conventions knowing that the trial Statistical Analysis Plan is likely unavailable and not always applicable to IDMC analyses in light of the nature of interim data compared to the propose of the final study report after database lock. The biostatistician(s) leading the reporting to the IDMC during Closed sessions should be intimately acquainted with the data, which can be best achieved by playing an active role in the data programming and analysis efforts.

Qualities of a Good SDAC

EFFECTIVE COMMUNICATION SKILLS:

Clear communication with other stakeholders, especially IDMC members, but also sponsors and sometimes regulatory agencies, is crucial.

This includes the ability to convey complex statistical concepts in an understandable way to non-biostatisticians.

The independent biostatistician from the SDAC should be able to guide the IDMC members through the study, answer questions, and prioritize ad hoc requests.

It is also important to note that effective communication extends to written language, as they should review (or write) meeting minutes, ensuring clarity rather than just providing bulleted lists.

TIMELY AND EFFICIENT REPORTING WITH ADVANCED ANALYSIS TOOLS:

The SDAC should provide timely, accurate statistical reports prepared with validated, advanced statistical software, which is essential for decision-making during the course of the trial.

The SDAC must be capable of managing interim or incomplete data and implement “defensive” coding practices.

This includes anticipating data changes and providing quick cleaning solutions to make sure the reports for the IDMC are interpretable.

In addition, the SDAC must comply with 21 CRF Part 11 (Title 21 of the Code of Federal Regulations), which governs Electronic Records and Electronic Signatures.

The team must also possess expertise in using Medical Dictionary for Regulatory Activities (MedDRA) and Standardized MedDRA Queries (SMQs), along with familiarity with FDA Medical Queries (FDA FMQs) to effectively monitor safety trends throughout the trial

Qualities of a Good SDAC

INDEPENDENCE:

UNBIASED AND INDEPENDENT FROM SPONSORS

Independence from the trial sponsors is essential to avoid any potential conflicts of interest and ensure regulators of the robustness of the trial and its results.

A good SDAC operates independently in concert with the IDMC, ensuring that the analysis is unbiased and objective, and the IDMC can act swiftly without potentially alerting the Sponsor to unblinded information, which is crucial for maintaining the integrity of the trial.

It is important to note that anyone involved in the design or or ongoing conduct of the trial should not be part of the unblinded SDAC team or IDMC.

PROACTIVENESS

ANTICIPATING NEEDS AND QUESTIONS

A proactive SDAC anticipates the needs and questions of IDMC members, as well as solicits feedback from the members on further editorial choices to the report (treating it as a living, evolving, and flexible tool).

By reviewing the cumulative and progressive data and preparing additional analyses and data visualizations, they ensure the IDMC has all the information needed to make informed decisions quickly and effectively.

Risks of Sponsor-led Programming

PRACTICAL DIFFICULTIES



When the sponsor is responsible for programming, it is often because they wish to use their Clinical Study Report (CSR) programs for the IDMC.

However, CSRs and IDMC reports serve different purposes, and the analyses required for each can vary significantly. Given that IDMC reports evolve over time as the dataset grows and trends emerge, it is crucial to maintain flexibility in modifying the programs.

If the sponsor leads the programming and the SDAC only manages the unblinding, the SDAC is faced with two problematic options: either inform the sponsor of IDMC-requested changes (which jeopardizes the confidentiality of the closed session) or modify the sponsor's programs with every transfer, leading to significant inefficiencies.

CONFLICTS OF INTEREST:

Sponsors naturally have an interest in the success of their trials, which may present challenges in ensuring complete objectivity.

This situation can potentially affect the trustworthiness of the data and the conclusions drawn from it. Implementing safeguards is essential to maintain the integrity of the trial.

Even without malicious or willful misconduct, the appearance of a conflict of interest can be just as damaging to the integrity of the trial.

Advantages of an Independent Programming by SDAC

ENSURES DATA RELIABILITY:

An independent SDAC dedicated to the trial ensures that all data is handled and analyzed with the highest standards of accuracy and objectivity. This approach minimizes the risk of errors and biases, providing more reliable results. Additionally, having an independent SDAC makes it operationally easier to protect the blind, as they can manage data and analyses without involving the sponsor, reducing the risk of unintentional breaches in confidentiality.

UNBIASED ANALYSIS

By keeping the programming and data analysis independent of the sponsor, the SDAC can provide unbiased and objective insights. This independence is crucial for the credibility of the trial outcomes and the recommendations made by the IDMC.

CONCLUSION

The role of a good SDAC is indispensable in clinical trials.
By ensuring expertise, independence, and flexibility, an effective SDAC enhances the reliability and integrity of trial data.

It is essential that programming be not only led by the SDAC but also tailored specifically to the needs of the IDMC, rather than relying on the CSR shells or Statistical Analysis Plan (SAP).

This tailored approach, combined with the SDAC's ability to adapt to evolving data and IDMC requests, ensures unbiased and credible trial outcomes.

Given the complexities and imperfections of interim data, **it is imperative that an SDAC be an active and informed participant in the monitoring process with the IDMC**. By adhering to these principles, stakeholders can significantly improve the quality and success of their clinical trials.

5

Crafting **Effective IDMC Reports**

Qualities of a Good Report

A WELL-CRAFTED REPORT PROVIDES THE IDMC WITH THE NECESSARY INFORMATION TO MAKE INFORMED DECISIONS WITHOUT OVERWHELMING THEM WITH UNNECESSARY DETAILS.

This section explores the qualities of a good IDMC report, focusing on tailored content, highlighting key data, and ensuring clarity and conciseness.

QUALITIES OF A GOOD REPORT

There are usually two types of reports that the IDMC receives:

OPEN REPORT:

If applicable, this report should be provided to the sponsor and discussed during the open session. It should not present information by treatment groups; instead, all information is pooled across all treatment groups to maintain the masking of treatment assignment.

It focuses on trial conduct issues such as status of recruitment, baseline characteristics, ineligibility rate, accuracy and the speed of data submissions, and other administrative information. Depending on the situation, other details may also be shared.

However, it's important to ensure that no unblinding occurs, and that the IDMC agrees that such additional data is shared in the open report (this will be aligned with the Charter, which is approved by the IDMC members and the sponsor as well).

CLOSED REPORT:

This report is presented during the closed session, attended only by the IDMC and the SDAC members.

The Independent Biostatistician from the SDAC presents the report to the IDMC. The report presents comparative analyses on safety (and efficacy too, if relevant and previously agreed) by treatment group and is the basis for the recommendations the IDMC will make to the sponsor.

Note that the SDAC and IDMC should be fully unblinded; however, using semi-masked treatment labels (e.g., 'Group A' and 'Group B') in the report can be advisable to prevent accidental unblinding.

Tailored Content

CUSTOMIZATION TO IDMC NEEDS:

A good IDMC report is tailored to the specific needs of the IDMC, differing significantly from final analysis reports intended for regulatory submission.
These reports should focus on providing the IDMC with actionable insights and data necessary for interim decision-making.

RELEVANT DATA:

- Include only data pertinent to the current phase of the trial and the specific questions or concerns of the IDMC.
- Avoid overloading the report with superfluous information that can distract from the critical issues at hand.
- Some data important at the beginning of the trial, such as the information on rates of recruitment, might no longer be necessary. If that is the case (and the IDMC agrees), it can be either deleted or included in an appendix. If possible, the IDMC report should generally be under 100 pages long with additional appendices if necessary.

Highlighting Key Data

EXECUTIVE SUMMARY:

If agreed by all stakeholders, the closed report can have a concise Executive Summary at the beginning, highlighting the most critical data points and findings (guide, but not interpret).

This summary should provide a quick overview of the trial's current status, including key safety and efficacy metrics, as well as serve as a roadmap to later report sections. For example, as recommended by DeMets and Wittes (2022), this one-to-two-page summary should include data on the number of patients entered, their disposition and adherence to study outcome, the primary (when relevant) and maybe some secondary outcomes, and relevant serious adverse events.

The report might also include the Executive Summary from previous meetings. That said, some IDMCs may view the Executive Summary as too biased or suggestive and prefer to either first agree to the content of it or otherwise exclude it from the report altogether.

GRAPHICAL PRESENTATIONS:

Using graphical presentations, such as charts and graphs, to clearly illustrate trends and significant findings, while maintaining backup tables in an organized appendix for reference when needed, is a strategy that is sometimes encouraged.

Visual aids can make complex data more accessible and understandable for IDMC members.

APPROPRIATE DATA CATEGORIZATIONS:

Categorize data appropriately to facilitate easy navigation and focus.
For instance, segregate safety data from efficacy data, and provide summaries for each category to highlight the most important findings.

The order and style of presentation of the data may evolve appropriately overtime, recognizing that initial data can be too sparse for planned table presentations and some presentations become less important over time (e.g., demographics after enrollment is complete).

Clarity and Conciseness

UNDERSTANDABLE LANGUAGE:

Ensure that the report is written in clear and understandable language, avoiding technical jargon that might confuse IDMC members who may not have a statistical background.

CONCISE REPORTING:

Aim for brevity without sacrificing important information.
The goal is to provide a comprehensive overview that can be quickly reviewed and understood by the IDMC, facilitating efficient decision-making.

FOCUSED CONTENT:

Keep the report focused on the critical aspects that require the IDMC's attention - without biasing the interpretation of the data.

CONCLUSION

Crafting effective IDMC reports is essential for the success of clinical trials. By tailoring content to the IDMC's needs, highlighting key data through executive summaries and graphical presentations, and ensuring clarity and conciseness, stakeholders can significantly enhance the decision-making process.

These principles help maintain the safety, integrity, and efficiency of clinical trials, ultimately leading to better outcomes for patients and sponsors alike.

6

The Role of IDDI: **Expertise & Support**

Expertise and Support

IDDI PLAYS A PIVOTAL ROLE AS THE SDAC IN SUPPORTING IDMCS BY OFFERING EXPERIENCED INDEPENDENT BIOSTATISTICIANS WHO CREATE TAILORED REPORTS FOR COMMITTEE REVIEW.

IDDI enhances IDMC efficiency through specialized tools and methodologies, ensuring that clinical trials are conducted with the highest standards of safety and integrity. These elements are essential for any SDAC to effectively support IDMCs.

INDEPENDENT STATISTICAL EXPERTISE:

IDDI's team of biostatisticians is **independent of trial sponsors**, ensuring unbiased and reliable data analysis.

COLLABORATIVE APPROACH:

Working closely with IDMC members to succinctly **tell the story of the data** and support their decision-making processes.

EXPERT ADVICE AND CONSULTATION:

IDDI helps pharmaceutical companies and biotech companies **strategically organize their IDMCs**, and it does that by offering **consultancy services** from seasoned professionals who bring decades of experience in clinical trials, IDMC operations, and regulatory statistics.

IN-DEPTH KNOWLEDGE:

Biostatisticians with **extensive experience** in designing and analyzing clinical trials, capable of handling complex data and providing clear, actionable insights.

ADVANCED STATISTICAL TOOLS:

IDDI provides **cutting-edge statistical tools** that facilitate thorough and efficient data analysis, specifically for IDMCs, to **enhance the accuracy and speed** of interim data reviews. These tools include a **library of dozens** of **various graphs, tables and listings** with various layouts, adaptable to any type of disease, and pre-programmed for **immediate use**.

Additionally, IDDI has developed **in-house software** that can **combine hundreds of outputs** into a **well-designed**, **easy-to-read main report**, accompanied by an appendix that complements the information (as detailed in Chapter 5). These reports **allow IDMC members to access relevant information quickly** and efficiently, *without the need to search through hundreds or even thousands of pages*.

Expertise and Support

TO ENSURE THE SUCCESS AND INTEGRITY OF YOUR CLINICAL TRIALS, IT IS CRUCIAL TO IMPLEMENT BEST PRACTICES FOR IDMCS.

At IDDI, we have been navigating the complexities of IDMCs for over three decades,

If you're unsure how to plan or manage an IDMC for your trial, we are here to assist.

We are dedicated to helping our clients ensure the highest standards of safety and integrity in their clinical trials.

280+
SUCCESSFULLY EXECUTED
IDMCs

COMBINE EXPERT CONSULTATION WITH INDEPENDENT STATISTICAL EXPERTISE:

Leverage the expertise of seasoned independent professionals to address specific challenges and improve decision-making processes.

Reach out to **Emmanuel Quinaux**, Biostatistics Services Director at IDDI, at emmanuel.quinaux@iddi.com to leverage our expertise in training, consultation, and providing specialized biostatisticians to optimize your trial oversight and outcomes.

References

1. Friedman, LM, Furberg, CD, DeMets, DL, Reboussin, DM, Granger, CB. (2015) Fundamentals of Clinical Trials. 5th Edition, Springer, New York, Dordrecht, London. https://doi.org/10.1007/978-3-319-18539-2.
2. ICH E6 (R2) Good clinical practice - Scientific guideline. June 2017. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-good-clinical-practice-e6r2-step-5_en.pdf
3. ICH E9 statistical principles for clinical trials - Scientific guideline. September 1998. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf
4. Guidance for Clinical Trial Sponsors. Establishment and Operation of Clinical Trial Data Monitoring Committees. March 2006. https://www.fda.gov/media/75398/download
5. Use of Data Monitoring Committees in Clinical Trials. Guidance for Industry. DRAFT GUIDANCE. February 2024. https://www.fda.gov/media/176107/download
6. DeMets DL and Wittes J. Data monitoring committee interim reports: We must get there soon! *Clin Trials* 2022; 19(1): 107-111.
7. SCT DMC Training. Society for clinical trials, https://www.sctweb.org/dmctraining/

ABOUT IDDI

IDDI is the center of excellence in **regulatory statistics and clinical data science** with deep expertise in handling complex data challenges **from trial design through to regulatory submission**.

We support pharmaceutical, biotech, and medical device/ diagnostic companies with:

- Regulatory statistics
- High-level strategy consulting
- Clinical trial design
- Randomization and Trial Supply Management (RTSM)
- Clinical data management
- Electronic Data Capture (EDC)
- Biostatistical services

With **1400+** Phase I-IV clinical trials, we are a therapy-focused CRO working mainly in CNS diseases, oncology, ophthalmology, and orphan drugs.

VISIT OUR WEBSITE FOR MORE INFORMATION ABOUT IDDI

www.IDDI.com

Raleigh, NC - USA
+1 984 227 8599

Louvain-la-Neuve, BELGIUM
+32 (0) 10 61 44 44

info@iddi.com